Mr. John Hennessy:

Interchangeability is the key, in the sense of the ability to switch to generic products versus branded products. The legislation appeared in 2013 to enable that process and since then the process has accelerated significantly. The overall figure took us from approximately 20% to 30% of generic usage in Ireland to upwards of 80% or 90%, especially for high-volume products.

Another area where progress will be found relates to high-technology medicines, the point under discussion today. The implementation of the Comptroller and Auditor General's report will help us to secure some price reductions in that area. However, that is the branded area, which is more difficult.